1. Home
  2. CANF vs LEDS Comparison

CANF vs LEDS Comparison

Compare CANF & LEDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • LEDS
  • Stock Information
  • Founded
  • CANF 1994
  • LEDS 2005
  • Country
  • CANF Israel
  • LEDS Taiwan
  • Employees
  • CANF N/A
  • LEDS 116
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • LEDS Semiconductors
  • Sector
  • CANF Health Care
  • LEDS Technology
  • Exchange
  • CANF Nasdaq
  • LEDS Nasdaq
  • Market Cap
  • CANF 13.5M
  • LEDS 13.6M
  • IPO Year
  • CANF N/A
  • LEDS 2010
  • Fundamental
  • Price
  • CANF $0.66
  • LEDS $1.66
  • Analyst Decision
  • CANF Strong Buy
  • LEDS
  • Analyst Count
  • CANF 2
  • LEDS 0
  • Target Price
  • CANF $14.00
  • LEDS N/A
  • AVG Volume (30 Days)
  • CANF 314.0K
  • LEDS 35.0K
  • Earning Date
  • CANF 08-29-2025
  • LEDS 07-11-2025
  • Dividend Yield
  • CANF N/A
  • LEDS N/A
  • EPS Growth
  • CANF N/A
  • LEDS N/A
  • EPS
  • CANF N/A
  • LEDS N/A
  • Revenue
  • CANF $674,000.00
  • LEDS $31,108,000.00
  • Revenue This Year
  • CANF $461.72
  • LEDS N/A
  • Revenue Next Year
  • CANF N/A
  • LEDS N/A
  • P/E Ratio
  • CANF N/A
  • LEDS N/A
  • Revenue Growth
  • CANF N/A
  • LEDS 485.62
  • 52 Week Low
  • CANF $0.63
  • LEDS $0.92
  • 52 Week High
  • CANF $3.24
  • LEDS $3.16
  • Technical
  • Relative Strength Index (RSI)
  • CANF 12.02
  • LEDS 25.94
  • Support Level
  • CANF $1.00
  • LEDS $1.68
  • Resistance Level
  • CANF $1.05
  • LEDS $1.95
  • Average True Range (ATR)
  • CANF 0.05
  • LEDS 0.16
  • MACD
  • CANF -0.04
  • LEDS -0.05
  • Stochastic Oscillator
  • CANF 5.86
  • LEDS 0.00

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About LEDS SemiLEDS Corporation

SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.

Share on Social Networks: